By the Top Tier Newswire AI Desk · July 24, 2026 at 9:39 AM ET · reviewed against 1 wire stories
SURGERY PARTNERS INC (SGRY) is drawing unusual attention today. Our newswire has captured 1 story on SGRY across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 42/100).
Why SGRY stock is up today
Surgery Partners Inc. (SGRY) rose 6.18% to $16.16 in early trading on July 24, 2026, driven by the company's announcement of a $1.15 billion agreement to sell its ownership interests in two Idaho Falls facilities. The deal with Intermountain Health includes Mountain View Hospital and Idaho Falls Community Hospital, with Surgery Partners receiving approximately $795 million in total consideration. The transaction is expected to close on July 21, 2026, and the company reaffirmed its FY2026 sales guidance, excluding the impact of the transaction.
What Happened
Surgery Partners and Intermountain Health entered into a definitive agreement to divest the ownership interests in the two hospitals. The agreement was filed with the SEC under an 8-K form, disclosing the material terms and financial details of the deal. The company emphasized that the transaction aligns with its strategic focus and will provide capital for future growth. The news was widely covered in the financial media, with reports highlighting the reaffirmed sales guidance and the financial terms of the deal. The stock opened at $15.26 and quickly surged to a session high of $17.00 before settling at $16.16.
What The Data Shows
The stock's intraday session showed strong early momentum, with a high of $17.00 at 9:00 AM ET and a low of $15.24 at 9:05 AM ET. The volume of 0.1 million shares traded so far is equal to 0.1 times the 3-month daily average, indicating moderate participation. SGRY has a market cap of $2.0 billion and a 52-week range of $11.41 to $24.10. The company remains unprofitable with a trailing twelve-month EPS of -0.60 and a net margin of -2.3%, but revenue grew by 5.4% in the same period.
What To Watch
The market will continue to monitor the company's FY2026 earnings performance and any further developments related to the divestiture. Surgery Partners has a history of reaffirming its guidance, and the impact of this transaction on its financials will be closely observed in the coming quarters.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.